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Most previous studies of prostate cancer have not taken into account that men in the studied populations are also at risk of
competing event, and that these men may have different susceptibility to prostate cancer risk. The aim of our study was to
investigate heterogeneity in risk of prostate cancer, using a recently developed latent class regression method for competing
risks. We further aimed to elucidate the association between Type 2 diabetes mellitus (T2DM) and prostate cancer risk, and to
compare the results with conventional methods for survival analysis. We analysed the risk of prostate cancer in 126,482 men
from the comparison cohort of the Prostate Cancer Data base Sweden (PCBaSe) 3.0. During a mean follow-up of 6 years 6,036
men were diagnosed with prostate cancer and 22,393 men died. We detected heterogeneity in risk of prostate cancer with
two distinct latent classes in the study population. The smaller class included 9% of the study population in which men had a
higher risk of prostate cancer and the risk was stronger associated with class membership than any of the covariates included
in the study. Moreover, we found no association between T2DM and risk of prostate cancer after removal of the effect of infor-
mative censoring due to competing risks. The recently developed latent class for competing risks method could be used to
provide new insights in precision medicine with the target to classify individuals regarding different susceptibility to a particu-
lar disease, reaction to a risk factor or response to treatment.
Introduction
Underlying assumptions in most common methods for sur-
vival analysis are that censoring is non-informative and that
the association between risk factors and the event of interest
is homogenous in the population studied.1 However, these
assumptions are often violated or neglected. First, informative
censoring may happen when the studied risk factor (e.g.,
smoking, obesity, metabolic syndrome) is associated with
death and a shorter life-expectancy.2–4 Methods based on
competing risk analysis can provide reliable real-life estimates
of risk in these study settings, but results are often difﬁcult to
interpret in terms of etiological hypotheses,5,6 especially if the
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risk factor is associated with both time to death and the risk
of the disease under study. Secondly, risk factors or other
studied covariates (e.g. treatments, drugs, and dietary expo-
sures) may have different associations with the risk within
sub classes of the population studied,7,8 and previous reports
of heterogeneity in cancer risk suggested that the majority of
the cases are arising from a minor susceptible part of the
population.9 Thus, there may be latent classes within a popu-
lation with a known or unknown geno- or phenotype that
render them to higher susceptibility of disease, or high risk
in association with a speciﬁc covariate, or positive or negative
response to a speciﬁc treatment, in line with the theories
behind precision medicine.10
Researchers investigating metabolic aberrations, metabolic
diseases, or drugs for metabolic diseases, and risk of prostate
cancer are facing a complex task. Observational studies sug-
gest that men with Type 2 diabetes mellitus (T2DM),11–17
and men on anti-diabetic drugs,18–20 have a decreased risk of
developing prostate cancer. Moreover, other studies indicate
that men with metabolic aberrations have a higher risk of
aggressive or fatal prostate cancer.21–24 Due to the higher age
when prostate cancer generally occurs, competing risk in
terms of death is an issue,25,26 especially since metabolic dis-
ease is associated with a shorter life-expectancy. One previous
study concluded that individuals with diabetes at a given age
have a smaller lifetime risk of cancer than individuals with-
out diabetes at the same age, attributable to the higher mor-
tality rates among individuals with diabetes.27 Moreover, they
noted that differences in cancer occurrence between individu-
als with and without diabetes were a quantitatively smaller
problem than the differences in mortality between the two
groups.27 In line with these results, we have previously inves-
tigated prostate cancer risk in relation to other competing
causes of death and reported that the decreased risk of pros-
tate cancer among men with metabolic aberrations is of
much smaller quantity than the increased risk of death
among those men, as compared to men with normal meta-
bolic levels. 28 We have also used other methods for compet-
ing risks to investigate similar research questions with respect
to prostate cancer,29,30 but to the best of our knowledge there
is no established method that yields straight forward inter-
pretations to analyze etiological associations within these
study settings.
Based on these limitations in conventional survival analy-
sis some of the present authors recently developed a method
to handle competing risks and cohort heterogeneity based on
latent class analysis.31 The aim of the current study was to
investigate heterogeneity in risk of prostate cancer classiﬁed
into risk categories deﬁned by tumor characteristics at diag-
nosis by applying this method. We further aimed to elucidate
the etiological association between T2DM and risk of prostate
cancer, and to compare the results with results derived from
conventional methods for survival analysis.
Material and Methods
Participants
We applied a method based on latent class analysis for com-
peting risks,31 on a prospective cohort study in the compari-
son cohort of Prostate Cancer Data base Sweden (PCBaSe)
3.0. For each man with prostate cancer in the National Pros-
tate Cancer Register of Sweden, ﬁve prostate cancer-free men
were randomly selected from the background population into
the comparison cohort, matched on birth year and county of
residence.32 By using the Swedish 10-digit personal identity
number, the men were linked to a number of national health
care registers and demographic databases. The study was
approved by the Research Ethics Board at Umeå University,
Sweden.
For the current study, we selected men who entered the
comparison cohort between January 1, 2007, and December
31, 2009, and were between 55 and 84 years old. The men in
the study were followed from entry date until date of prostate
cancer diagnosis, date of death, or December 31 2014, which-
ever occurred ﬁrst. Time in follow-up was used as a timescale
in all analyses.
Covariates in study
We retrieved data from the National Patient Register on dis-
charge diagnoses from hospital admissions up to ten years
prior to the date of inclusion in the comparison cohort.
These data were used to calculate the Charlson Comorbidity
Index (CCI), categorised into no comorbidity (0), mild (1),
moderate (2), and severe (3 or more) comorbidity as
described previously.33,34 Data on educational level were
retrieved from the Longitudinal Integration Database for
Health Insurance and Labor Market Studies at Statistics Swe-
den, and were categorized into three groups based on dura-
tion of education: 9 years, 10–12 years, and 13 years,
which corresponded to elementary school, secondary school,
and higher education.35 Status of T2DM was deﬁned by anti-
diabetic drug prescriptions classiﬁed according to the Ana-
tomical Therapeutic Chemical Classiﬁcation System from the
What’s new?
Men with type 2 diabetes have a decreased risk of developing prostate cancer but metabolic disease is associated with a
shorter life expectancy. Here the authors applied a new method to handle competing risks and cohort heterogeneity and
found no association between type 2 diabetes mellitus and prostate cancer risk after isolating the effect from competing risks.
This method may support precision medicine by correctly classifying individuals regarding susceptibility to a particular cancer
or response to treatment.
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Prescribed Drug Register. We retrieved data of metformin
(A10BA or A10BD), insulin (A10A) and sulphonylurea
(A10BB), and classiﬁed T2DM status as users of no anti-
diabetic drugs, metformin, or insulin/sulphonylurea. This cat-
egorization were based on the national guidelines of diabetes
care and pattern of use of anti-diabetic drugs in Sweden.36
We used age at start of study, T2DM status, education level
and CCI as covariates in all analyses. T2DM status and CCI
were recorded at start of study. Covariates were transformed
to z-scores (mean 5 0, standard deviation 5 1) prior to
analysis.
Endpoints assessed
Data on prostate cancer diagnosis was obtained from the
National Prostate Cancer Register of Sweden which includes
information on date of diagnosis, age at diagnosis, tumour
stage and differentiation, serum levels of prostate-speciﬁc
antigen (PSA) at time of diagnosis, and primary treatment.31
Prostate cancer risk categories were deﬁned at diagnosis
according to a modiﬁcation of the National Comprehensive
Cancer Network Guideline:37 Low-risk: T1-2, Gleason score
of 2–6 and PSA < 10 ng/ml; intermediate-risk: T1-2, Gleason
score 7 and/or PSA 10–20 ng/ml; high-risk: T3 and/or Glea-
son score 8–10 and/or PSA 20–50 ng/ml; metastatic disease:
T4 and/or N1 and/or PSA 50–100 ng/ml (regional metasta-
ses) or M1 and/or PSA > 100 ng/ml (distant metastases).32
We clustered these risk categories into favorable-risk prostate
cancer (low- and intermediate-risk), and aggressive prostate
cancer (high-risk and metastatic disease).38 Date and cause of
death were obtained from the Cause of Death Register, and
deaths from cardiovascular diseases were deﬁned as codes
I00.0-I99.9 (International Classiﬁcation of Diseases, 10th revi-
sion). We used four endpoints in the analyses: favorable-risk
and aggressive prostate cancer, death of cardiovascular dis-
eases and death of other causes.
Survival analysis
We investigated heterogeneity in risk of prostate cancer, and
elucidated the association between T2DM status and risk of
prostate cancer to differentiate the effect of informative cen-
soring from competing endpoints, with the latent class model
for competing risks described previously,31 and also brieﬂy
described below. In comparison to conventional survival
models, the model does not assume homogenous associations
between covariates and endpoints and takes into account
simultaneous risks of all four endpoints. It assumes that the
study population may be comprised of one or several latent
classes, and that risk differences between classes are induced
by latent heterogeneity, that is heterogeneity not captured by
covariates, and can be quantiﬁed by relative frailty and/or
variability in associations of base hazard rates. The assump-
tion of proportional hazards is only made for each endpoint
and each latent class separately, but is not required to be
valid for the full study population collectively. If no latent
classes are found in the study population, the method will
automatically reduce to a model with similar settings as the
Cox proportional hazards model.
Associations with covariates and latent class membership
on risk of all endpoints were investigated by calculations of
hazard ratios (HR) from the latent class model for competing
risk analysis. The HR for latent class membership are deﬁned
by relative frailties. The calculations were performed with the
software package Advanced Latent Class Prediction and
Competing Risk Analysis version 0.2, (ALPACA, A.C.C.
Coolen, M. Rowley, M. Inoue, London, UK). The results
from the latent class model for competing risk analysis were
compared to HR from Cox and Fine and Gray regression
models.39 In the Cox models, we calculated the risk of each
endpoint separately and censored for all other endpoints,
while in Fine and Gray regression models, all other endpoints
were handled as competing risks. These models were calcu-
lated by STATA MP/2 version 14 (StataCorp LP, College Sta-
tion, Texas).
Latent class model for competing risk
As described in detail previously,31 latent class analysis in
ALPACA is performed in two stages: during the parameter
estimation stage, model estimates are obtained for many can-
didate models, covering a range of latent classes, base hazard
rate complexities, and degrees of permitted heterogeneity.
Due to its stochastic nature, this process is performed multi-
ple times until consistent estimates are obtained. At the
model selection stage the relative probabilities of all candidate
models are computed and the model with the greatest proba-
bility of describing the study data, the optimal model, is
determined. Bayesian model selection balances the need for
model complexity with the evidence available in the data to
support such complexity. The base hazard rate parametrisa-
tion is based on a spline construction, where the inferred
number of spline points increases with the complexity of the
base hazard rate. In our study, we included latent class mod-
els with one to four latent classes, and with up to ten spline
time points.
Based on the optimal model, we analysed the base hazard
rate, covariate HRs, latent class membership HRs (relative
frailty), and survival functions, both under the inﬂuence of
competing risks (crude) and isolated from the effect of cen-
soring due to competing risks (marginal), separately for each
latent class. We here quantiﬁed the association of the covari-
ates on the endpoints by calculating covariate HRs and quan-
tiﬁed the association attributed by the class membership on
the endpoints by calculating class membership HRs, that is
the association of relative frailty due to factors not accounted
for in our study. Characteristics of study participants were
analysed in relation to the most probable latent class they
were assigned to. In order to assess the effect of censoring
due to competing risks we graphically compared the crude
and marginal survival functions.
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Results
Mean age at start of study was 70 years (SD 5 7 years). Dur-
ing a mean follow-up of 6 years (SD 5 2), 3,397 men were
diagnosed with favorable-risk prostate cancer, 2639 men with
aggressive prostate cancer, 9,165 died of cardiovascular dis-
eases and 13,228 died of other causes without no previously
diagnosis of prostate cancer. Baseline characteristics of the
full study population are shown in Table 1.
Based on the latent class model for competing risks, the
study population consists with high probability of two dis-
tinct latent classes. Class 1 included 115,623 (91%) men in
the study, while Class 2 included 10,859 (9%) men. Men in
Class 1 were typically younger and with fewer comorbidities
than men in Class 2, (Supporting Information Table 1). At
the end of follow-up, 85% of the men in Class 1 were alive
and free of prostate cancer, 6% had died of cardiovascular
diseases and 9% from other causes, while in Class 2 all men
were either dead, 23% from cardiovascular diseases and 24%
from other causes, or had been diagnosed with prostate can-
cer (31% with favorable-risk and 22% with aggressive pros-
tate cancer; Table 2).
Men in Class 2 were frailer than men in Class 1 with
respect to the risk of all four endpoints. The relative frailty
between the classes was largest for favorable-risk and aggres-
sive prostate cancer, with HRs for class membership of 16.4,
95% conﬁdence interval: 7.1, 38.3, for favorable-risk prostate
cancer and 8.1, 95% conﬁdence interval: 4.5, 14.7, for aggres-
sive prostate cancer. All covariate HRs were weaker than the
class membership HRs on risk of favorable-risk and aggres-
sive prostate cancer, (Table 3).
We found no associations between T2DM status and risk
of favorable-risk and aggressive prostate cancer in any of the
classes, but an association with death of cardiovascular dis-
eases and other causes in Class 1, and in Class 2 an inverse
association with death of other causes. By visually observing
the crude and marginal survival functions for T2DM status,
we found that informative censoring due to competing risks
had opposite effects on the survival curves in the both classes
(Figure 1). The scales were different between the ﬁgures and
the differences between the crude and marginal survival
curves were far higher in Class 2. In that class, the crude sur-
vival curve (under inﬂuence of competing risks) underesti-
mated the risk as compared to the marginal survival curve
(isolated from the effect of competing risks), while in Class 1
we found a smaller, but opposite effect.
In the analysis of HRs from Cox regression analysis, we
found that age, T2DM status and the CCI were inversely
associated, and education level positively associated to
favorable-risk prostate cancer (Supporting Information Table
2a). Moreover, age was positively associated with aggressive
Table 1. Baseline characteristics of the study population of 126,482 men
N %
Age at start of study 55–59 years 12,511 10
60–64 years 26,095 21
65–69 years 29,774 24
70–74 years 24,450 19
75–79 years 19,653 16
80–84 years 13,999 11
Year of selection into comparison cohort 2007 39,957 32
2008 39,355 31
2009 47,170 37
Educational level1 Low2 52,496 42
Intermediate 47,147 37
High 26,839 21
Charlson Comorbity Index No comorbidity (0) 93,671 74
Mild comorbidity (1) 16,834 13
Moderate comorbidity (2) 9,313 7
Severe comorbidity (3 or more) 6,664 5
Type 2 diabetes mellitus status No anti-diabetic drugs 111,900 88
Metformin 4,552 4
Insulin/sulphonylurea3 10,030 8
1Educational level categorised as low (9 years of school), intermediate (10–12 years), and high (13 years), corresponding to mandatory school,
high school, and college or university.
2Educational level missing for 2006 men (2%); these men were included in the group with low educational level.
3Ordered variable such as men in the insulin/sulphonylurea group could also use metformin.
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prostate cancer and the CCI inversely. Age, T2DM status use
and the CCI were positively associated with death of cardio-
vascular diseases and other causes, while education levels
were inversely associated. Results based on the sub distribu-
tion HRs from Fine and Gray regression were similar to the
results based on Cox regression (Supporting Information
Table 2b).
Discussion
By applying the recent latent class analysis method for com-
peting risks,31 we found heterogeneity in risk of prostate can-
cer with two distinct latent classes in the study population.
The risk of prostate cancer, both favorable-risk and aggres-
sive, was stronger associated with latent class membership
than any of the included covariates (age, T2DM status, edu-
cation level and the CCI). The association with class mem-
bership included factors not accounted for in the study, that
is class-speciﬁc relative frailty. Moreover, we found no associ-
ation for T2DM status and prostate cancer risk after isolating
the effect of censoring due to competing risks, in contrast to
the ﬁndings in a conventional survival analysis.
The main strength of the recent method is the possibility
to systematically map cohort heterogeneity and the effect of
censoring due to competing risks, without violating underly-
ing statistical assumptions. The only assumption made is that
any competing risk censoring effects are a consequence of
such heterogeneity. Moreover, the method is developed to
assess results with straightforward etiological interpretations,
in contrast to sub distribution HRs based on competing risk
regression.5,6 By use of this new method it is possible to
detect frail sub classes in the study population with class-
speciﬁc risk factors to the event of interest, and to detect sce-
narios where competing risk may mask or bias etiological
associations, such as false aetiology or false protectivity.9 A
limitation is that information in the covariates can only
give an indication about class membership retrospectively.
Another limitation is the crude deﬁnition of T2DM status
based on data of anti-diabetic drug use without accounting
Table 2. Endpoint distribution and frailty differences in the two latent classes
Class 1 (91%,
N 5 115,623)
Class 2 (9%,
N 5 10,859)
Class membership2
Status at end of study N % N % Relative frailty1 HR (95% CI)
Alive and free of prostate cancer 98,053 85 0 0 NA NA
Diagnosis of favorable-risk prostate cancer 68 0 3,329 31 2.8 16.4 (7.1, 38.3)
Diagnosis of aggressive prostate cancer 211 0 2,428 22 2.1 8.1 (4.5, 14.7)
Death of cardiovascular diseases 6,642 6 2,523 23 0.1 1.1 (1.6, 1.7)
Death of other causes 10,649 9 2,579 24 0.5 1.6 (1.2, 2.2)
1Relative contribution due to class membership defined as relative frailty factor 5 abs[frailty (Class 1)]-abs[frailty (Class 2)].
2Association due to class membership: HR 5 exp(relative frailty factor), 95% confidence intervals were calculated via z-scores from the averages
and standard deviations of the regression parameters.
Table 3. Statistical significant class-specific hazard ratios (HRs) for covariates and endpoints in the two latent classes. All covariates trans-
formed to z-scores (mean 5 0, SD 5 1) and endpoints are included in the models and HRs are calculated per unit increase
Covariate
Diagnosis of
favorable-risk
prostate cancer
Diagnosis of
aggressive
prostate cancer
Death of
cardiovascular
diseases
Death of
other causes
Class 1 Endpoint
Age 0.63 (0.46–0.85) 2.01 (1.27–3.19) 3.09 (2.73–3.50) 6.12 (5.11–7.34)
Type 2 diabetes mellitus status1 – – 1.16 (1.08–1.24) 1.25 (1.86–1.32)
Education level2 – – 0.68 (0.63–0.75) 0.79 (1.74–0.86)
Charlson Comorbidity Index3 – – 2.85 (2.56–3.17) 1.26 (1.15–1.38)
Class 2 Endpoint
Age 0.88 (0.79–0.98) 3.31 (2.76–3.97) 26.12 (11.55–59.10) 1.54 (1.36–1.87)
Type 2 diabetes mellitus status1 – – – 0.78 (0.69–0.89)
Education level2 1.33 (1.16–1.53) – 0.78 (0.67–0.93) 0.76 (0.64–0.90)
Charlson Comorbidity Index3 0.73 (0.58–0.92) 0.68 (0.50–0.92) 2.20 (1.83–2.66) 7.57 (5.45–10.52)
1Defined as 0 5 no anti-diabetic drugs, 1 5 metformin, 2 5 insulin or sulphonylurea.
2Defined as 1 5 low, 2 5 intermediate, 3 5 high educational level.
3Defined as 0 5 no comorbidities, 1, 2, 3 or more comorbidities.
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Figure 1. Marginal and crude survival curves separately for Type 2 diabetes mellitus (T2DM) status (a) in Class 1 and (b) Class 2 on risk of
(1) favorable-risk prostate cancer and (2) aggressive prostate cancer. Black lines are the crude survival curves under influence of competing
risks, gray lines are the marginal survival curves isolated from the effect of censoring from competing risks. If the crude and the marginal
survival curves are equal there are no effects of competing risks. If the crude survival curve shows worse survival than the marginal survival
curve, as in a1 and a2, there is an overestimation of the risk (false aetiology). If the crude survival curve shows better survival than the
marginal survival curve, as in b1 and b2, there is an underestimation of the risk (false protectivity). The crude survival curves are not class-
specific.
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for duration. In the current study, men with T2DM treated
with diet only is not included, and a minority of those classi-
ﬁed as T2DM might have Type 1 diabetes mellitus, however,
this deﬁnition of T2DM have been used before in a similar
setting.40 The results from our study are consistent with stud-
ies of frailty of cancers at other sites, where researchers have
suggested that a high proportion of cases may arise in a
minor susceptible part of the population.9,41–43 There is one
previous study of prostate cancer using the recently devel-
oped method where, in line with our results, the population
in that study also included two distinct latent classes; how-
ever, the frailer class consisted of 16% of the cohort as com-
pared to 9% in our study. 31,44 The difference in size for the
frailer class might be attributed to differences in the overall
cohort, as the study by Grundmark et al. included a younger
cohort with longer follow up, which may imply a higher risk
of developing prostate cancer.44 We speculate that men in
the frail class may have family history of prostate cancer,45,46
or an unknown risk factor.
Our conventional analysis of T2DM status and prostate
cancer risk showed an inverse association, in line with previ-
ous reports.18–20 The conventional analysis handles all events
other than prostate cancer as censored, and neglects the asso-
ciations with T2DM status and competing risks. To the best
of our knowledge, no previous studies have been able to
assess the etiological risk of T2DM and risk of prostate can-
cer, isolated from the effect of censoring from competing
risks. By use of the new method we identiﬁed the effect of
censoring due to competing risks and assessed etiological
association isolated from this effect. This resulted in a null
association for T2DM status with risk of prostate cancer. We
thus noted that the conventional analysis showed what has
previously been denoted as false protectivity.9,31 There are
other reports discussing issues with etiological association
after accounting for the effect of censoring from competing
risks, these studies have used the terms selection bias of sur-
vivors, or competing risk bias.2–4 Similar to our data, one of
these studies investigated the consistent inverse association
for smoking and the risk of malignant melanoma, and after
simulating and removing the effect of censoring from com-
peting risks, a null etiological association was detected.2
In conclusion, methods in conventional survival analysis
are often limited by assumptions that are rarely satisﬁed in
real life situations. In the current study we have applied a
recently developed method created for heterogeneous popula-
tions to calculate etiological risk estimates for prostate cancer
undisturbed of competing risks. In accordance with studies of
other cancer sites, we found that only a minor part of the
studied population had a higher risk of prostate cancer. In
line with the concept of precision medicine, this method can
detect classes of individuals that differ in their susceptibility
to a particular disease, their reaction to a certain risk factor
or their response to a speciﬁc treatment. These individuals
can be further investigated to ﬁnd clues for preventive or
therapeutic interventions.10
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